Annexins as potential targets in ocular diseases Strabismus
This special issue belongs to
|Research & Reviews: A Journal of Pharmaceutical Science|
Deadline for Manuscript Submission
|March 31st, 2023|
Deadline for Publication
|April 15, 2023|
Special Issue Description
Ca2+/phospholipid-binding proteins known as annexins (AnxAs) have undergone substantial research and are typically involved in several disorders. Although there is evidence for the distribution of AnxAs in the visual system, it is unclear exactly what these proteins do or which types of eye cells express these proteins.
Lexus is a key target in maintaining the homeostasis of the ocular tissue due to its pro-resolving functions in autoimmune, fibrotic, degenerative, viral, and angiogenic diseases. The important discoveries about the distribution and role of annexins in the eye's normal and diseased states are highlighted in this overview. They are appealing therapeutic candidates for the management of human strabismus illness due to their capacity to affect inflammatory responses.
Manuscript Submission information
Manuscripts should be submitted online by registering and logging in to this link. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed.
Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent on email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.